POAG puts pressure on the heart

Article

Patients with primary open-angle glaucoma (POAG) have a higher level of cardiovascular risk than in age-matched patients without glaucoma, according to a report published in a recent issue of Graefe's Archive for Clinical and Experimental Ophthalmology.

Patients with primary open-angle glaucoma (POAG) have a higher level of cardiovascular risk than in age-matched patients without glaucoma, according to a report published in a recent issue of Graefe's Archive for Clinical and Experimental Ophthalmology.

Nicola Orzalesi and colleagues from the OPTIME Study group, collected and analysed data from the medical history of 2,879 POAG patients and 973 age-matched controls, from 35 centres in Italy. Data relating to vascular risk factors were collected by means of a detailed questionnaire and all subjects underwent a complete ophthalmic examination with assessment of intraocular pressure (IOP), visual field, optic disc and systemic blood pressure. The European Society of Hypertension/European Society of Cardiology (ESH-ESC) guidelines were used to calculate the level of cardiovascular risk.

The POAG patients had significantly higher systolic and diastolic blood pressure, systolic perfusion pressure and IOP compared to the control group. However, diastolic perfusion pressure did not significantly differ between the groups. Myopia was more common in the POAG group (23% compared to 18%), as was a positive family history of glaucoma (26% compared to 12%). POAG patients also tended to have a higher cardiovascular risk than controls. A total of 63% of POAG patients and 55% of controls had a high or very high cardiovascular risk.

The authors found that patients with POAG do have a greater cardiovascular risk than those who do not have glaucoma.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.